Vol. 20/No. 16

Dejan Juric, MD, discusses the significance of the alpelisib approval and the importance of developing a plan for the management of adverse events.

Although hormonal manipulation was an established part of breast cancer treatment long before the underlying biology of the disease was characterized, advancements in the understanding of estrogen receptor signaling are rapidly changing the therapeutic landscape.

A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.

Residents of Indiana now have a National Cancer Institute–designated Comprehensive Cancer Center in their state, and Floridians have another designated Cancer Center in theirs. Both institutions, the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis and the University of Miami Sylvester Comprehensive Cancer Center, are OncLive® Strategic Alliance Partners.

Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Genomic profiling provides evidence of measurable residual disease in patients with acute myeloid leukemia and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation.

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.

Particularly in the oncology arena, there are several serious scientific, ethical, and pragmatic concerns associated with ongoing reliance on placebo-controlled studies.